Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COMMERCIAL MANUFACTURING AGREEMENT This COMMERCIAL MANUFACTURING AGREEMENT (this "Agreement") is made and...Commercial Manufacturing Agreement • August 8th, 2006 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 8th, 2006 Company Industry Jurisdiction
BACKGROUNDCommercial Manufacturing Agreement • April 4th, 2008 • Xanodyne Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledApril 4th, 2008 Company Industry Jurisdiction
Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug ProductsCommercial Manufacturing Agreement • June 9th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 9th, 2016 Company IndustryThis agreement follows a successful multi-year clinical manufacturing relationship and provides bluebird bio with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. This facility is currently under construction for the clinical and commercial supply of viral vectors and virally-modified cell therapy products.
COMMERCIAL MANUFACTURING AGREEMENT Salix Pharmaceuticals, Inc., Mesalamine Controlled Release CapsulesCommercial Manufacturing Agreement • August 17th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 17th, 2009 Company Industry JurisdictionThis Commercial Manufacturing Agreement (“Agreement”) is made effective as of this 9th day of September, 2008 (“Effective Date”), by and between Salix Pharmaceuticals, Inc., a California corporation, with a place of business at 1700 Perimeter Park Drive, Morrisville, NC, 27560 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).
EX-10.47 4 d291060dex1047.htm COMMERCIAL MANUFACTURING AGREEMENT CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE...Commercial Manufacturing Agreement • May 5th, 2020 • Puerto Rico
Contract Type FiledMay 5th, 2020 JurisdictionTHIS AGREEMENT is executed as of this 19th day of December, 2006 and effective as of June 1, 2006 (the “Effective Date”), by and between MOVA Pharmaceutical Corporation (“MOVA”), a corporation organized under the laws of the Commonwealth of Puerto Rico, having its principal place of business at Villa Blanca Industrial Park, State Road No. 1, Km. 34.5,Caguas, Puerto Rico, and Depomed, Inc. (“DEPOMED”), a corporation organized under the laws of the State of California, having its principal place of business at 1360 O’Brien Drive, Menlo Park, California 94025. MOVA and DEPOMED each shall sometimes be referred to herein sometimes as a “Party” and collectively as the “Parties.”
EX-10.75 3 dex1075.htm COMMERCIAL MANUFACTURING AGREEMENT [ * ] = Certain information on this document has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the...Commercial Manufacturing Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis Commercial Manufacturing Agreement (“Agreement”) is made as of this 10th day of September, 2009 (“Effective Date”), by and between InterMune, Inc., a Delaware corporation, with a place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).
AMENDING AGREEMENTCommercial Manufacturing Agreement • May 8th, 2014 • Insmed Inc • Pharmaceutical preparations • New York
Contract Type FiledMay 8th, 2014 Company Industry JurisdictionThis Amending Agreement (this “Amending Agreement”) is entered into and effective this 13th day of March, 2014 (the “Effective Date”), by and between Therapure Biopharma Inc. (“Therapure”), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (“Insmed”), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a “party” and collectively as the “parties”.
COMMERCIAL MANUFACTURING AGREEMENT 1Commercial Manufacturing Agreement • May 6th, 2015 • Siga Technologies Inc • Pharmaceutical preparations
Contract Type FiledMay 6th, 2015 Company IndustryTHIS 2015 AMENDMENT TO COMMERCIAL MANUFACTURING AGREEMENT (the “2015 Amendment”), dated as of __ __________ 2015, is by and among SIGA Technologies, Inc., a Delaware corporation, having a place of business at 660 Madison Avenue, Suite 1700, New York, NY, 10065 (“Customer”), and Albemarle Corporation, a Virginia corporation, with a place of business at 451 Florida Street, Baton Rouge, LA, 70801 (“Albemarle”).
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • March 16th, 2006 • Collagenex Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
Contract Type FiledMarch 16th, 2006 Company Industry JurisdictionThis Commercial Manufacturing Agreement (“Agreement”) is made this 30th day of December, 2005, by and between Cardinal Health PTS, LLC, having a place of business at 14 Schoolhouse Road, Somerset, NJ 08873 (“Cardinal Health”) and CollaGenex Pharmaceuticals, Inc. (“Client”), having its principal place of business at 41 University Drive, Suite 200, Newtown, PA 18940.
COMMERCIAL MANUFACTURING AGREEMENT (AVACOPAN)Commercial Manufacturing Agreement • November 9th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 9th, 2020 Company IndustryTHIS AGREEMENT (“Agreement”) is made and entered into as of August 17, 2020 (the “Effective Date”) by and between ChemoCentryx, Inc. a Delaware corporation, with offices at 850 Maude Avenue, Mountain View, CA 94043 (“Customer”), and Hovione LLC, with a mailing address at 40 Lake Drive, East Windsor, New Jersey 08520 (“Hovione”).
Addendum #3 to Commercial Manufacturing AgreementCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations
Contract Type FiledNovember 4th, 2014 Company IndustryThis Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective the 2nd day of July, 2014 by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and customer dated August 25, 2011, as amended December 21, 2012 and July 1, 2013 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.
Addendum to Commercial Manufacturing AgreementCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations
Contract Type FiledNovember 4th, 2014 Company IndustryThis Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective this ____ day of _____________, 2012, by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and Customer dated August 25, 2011 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.
ContractCommercial Manufacturing Agreement • March 17th, 2008 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledMarch 17th, 2008 Company IndustryNOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 4th, 2014 Company Industry JurisdictionThis COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of __________, 2011 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 35 E. 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 451 Florida Street, Baton Rouge, Louisiana 70801. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • March 6th, 2019 • Siga Technologies Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 6th, 2019 Company Industry JurisdictionThis COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of October 1, 2018 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 31 East 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 4350 Congress Street, Suite 700, Charlotte, North Carolina 28209. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.
MOVA Pharmaceutical Corporation and Depomed, Inc. COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • March 16th, 2007 • Depomed Inc • Pharmaceutical preparations • Puerto Rico
Contract Type FiledMarch 16th, 2007 Company Industry JurisdictionTHIS AGREEMENT is executed as of this 19th day of December, 2006 and effective as of June 1, 2006 (the “Effective Date”), by and between MOVA Pharmaceutical Corporation (“MOVA”), a corporation organized under the laws of the Commonwealth of Puerto Rico, having its principal place of business at Villa Blanca Industrial Park, State Road No. 1, Km. 34.5,Caguas, Puerto Rico, and Depomed, Inc. (“DEPOMED”), a corporation organized under the laws of the State of California, having its principal place of business at 1360 O’Brien Drive, Menlo Park, California 94025. MOVA and DEPOMED each shall sometimes be referred to herein sometimes as a “Party” and collectively as the “Parties.”
AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • November 19th, 2013 • Pharmacyclics Inc • Pharmaceutical preparations
Contract Type FiledNovember 19th, 2013 Company Industry
ContractCommercial Manufacturing Agreement • November 9th, 2012 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledNovember 9th, 2012 Company IndustryNOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
ADDENDUM 2 TO COMMERCAIL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations
Contract Type FiledNovember 4th, 2014 Company IndustryThis Addendum 2 to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective the 1st day of July, 2013 by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and customer dated August 25, 2011, as amended December 21, 2012 (collectively the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.
AMENDING AGREEMENTCommercial Manufacturing Agreement • October 29th, 2020 • INSMED Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 29th, 2020 Company Industry JurisdictionThis Amending Agreement (this “Amending Agreement”) is entered into and effective this 13th day of March, 2014 (the “Effective Date”), by and between Therapure Biopharma Inc. (“Therapure”), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (“Insmed”), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a “party” and collectively as the “parties”.
AMENDMENT NUMBER TWO TO AMENDING AGREEMENTCommercial Manufacturing Agreement • May 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2011 Company IndustryWHEREAS, the Parties have entered into a COMMERCIAL MANUFACTURING AGREEMENT dated as of OCTOBER 18, 2002 (hereinafter, the "AGREEMENT") for the manufacture of NPS ALLELIX proprietary product ALX-11 (also known as PREOS®), for which the active ingredient is recombinant human parathyroid hormone eighty-four (84) amino acids ("rhPTH"); and
AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • August 14th, 2014 • Pharmacyclics Inc • Pharmaceutical preparations
Contract Type FiledAugust 14th, 2014 Company Industry
COMMERCIAL MANUFACTURING AGREEMENT between NPS Pharmaceuticals, Inc. and Vetter Pharma International GmbH Dated as of December 21, 2009Commercial Manufacturing Agreement • January 15th, 2013 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 15th, 2013 Company IndustryTHIS QUALITY AGREEMENT, made and entered into as of the Commencement Date of the Commercial Manufacturing Agreement and attached thereto as Appendix 12 (the “QA”), by and between NPS and Vetter.